Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Brain Neoplasms × Basiliximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Hodgkin Disease 2 Glioblastoma 2 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hemoglobinuria, Paroxysmal 1 Gliosarcoma 1 Brain Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1 Anemia, Aplastic 1

Interventions

Temozolomide 86 Bevacizumab 57 Radiotherapy 54 Radiosurgery 36 Carboplatin 26 Magnetic Resonance Spectroscopy 24 Irinotecan 23 Etoposide 21 Surgical Procedures, Operative 19 Carmustine 18 Filgrastim 16 Lomustine 15 Erlotinib Hydrochloride 15 Vincristine 14 Cyclophosphamide 14 Radiation 13 Lapatinib 13 Cisplatin 13 Thalidomide 11 Sorafenib 11 Imatinib Mesylate 11 Trastuzumab 10 Surveys and Questionnaires 10 Nivolumab 10 Granulocyte Colony-Stimulating Factor 10 Aminolevulinic Acid 10 Thiotepa 9 Radiotherapy, Intensity-Modulated 9 Peripheral Blood Stem Cell Transplantation 9 Everolimus 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00626483 2021-03-09

REGULATe

Duke University

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡